Li Weiwei's practice areas mainly include private equity investment, fund establishment and post-fund management, fund liquidation, domestic and overseas capital markets, acquisitions and mergers, etc. Li Weiwei has extensive experience in fund establishment, operation and investment and financing business. She has established many blind pool funds and special funds on behalf of fund managers, and completed investment and financing transactions in a wide range of industries such as smart manufacturing, new energy, biomedicine, and consumption on behalf of many investment institutions and start-ups. Li Weiwei has won unanimous recognition from clients and peers for his professional, efficient, meticulous and patient practice style.
Practice Areas
Private equity investment, fund establishment and post-fund management, fund liquidation, domestic and overseas capital markets, mergers and acquisitions
Representative Performance
Domestic listing:
• Xiamen Wanli Stone Co., Ltd. domestic A-share IPO;
• Qianhe Flavor Food Co., Ltd.'s domestic A-share IPO;
• Shenzhen Xiongdi Technology Co., Ltd.'s domestic A-share IPO;
• Jilin Publishing Group Co., Ltd. applied for its first domestic public offering of A shares;
• Shenzhen Dacheng Technology Co., Ltd. was listed on the New Third Board;
• Jiangsu Aosaikang Pharmaceutical Co., Ltd. returned to the red chip market and IPOed on the A-share market;
• Hainan Jinpan Intelligent Technology Co., Ltd. de-red-chipped and returned to the A-share market through IPO, etc.
Overseas listing:
• China Zhi Pharmaceutical Holdings Limited Hong Kong red chip IPO;
• Ronshine China Holdings Limited Hong Kong red chip IPO;
• Q Technology (01478.hk) Hong Kong red chip IPO;
• Yiyuan Wine Holdings Limited Hong Kong red chip IPO;
• Huali University Group applied for Hong Kong red chip IPO, etc.
Acquisition and restructuring:
• Xilong Science Co., Ltd. acquired a domestic biological science company, a chemical reagent company, etc.;
• Xilong Science Co., Ltd. acquired Shanghai Aladdin Biochemical Technology Co., Ltd., a company listed on the New Third Board;
• Mango Creative Investment Management Co., Ltd. acquired a domestic technology company;
• Wanze Shares (000534) major asset sale;
• Guangdong Yingfeng Materials Technology Co., Ltd. acquired a domestic metal powder company;
• Vanke Group Co., Ltd. acquired a domestic breeding company, an agricultural company, etc.
Fund:
• Represented the fund manager in establishing a national science and technology fund;
• Represented the fund manager in establishing a new sub-fund manager in a joint venture with Jiangxi State-owned Capital Operation Holding Group Co., Ltd., and established a first-level equity blind pool fund with various government-guided funds as the main investors;
• Represented the fund manager in establishing multiple blind pool funds;
• Represented the fund manager in establishing multiple special funds;
• Shenzhen Qianyao Asset Management Co., Ltd. registered as a private equity fund manager;
• Shenzhen Qianhai Jinyue Investment Management Co., Ltd. registered as a private equity fund manager;
• Shenzhen Yongqian Asset Management Co., Ltd. registered as a private equity fund manager;
• Zhuhai Junsheng Equity Investment Management Co., Ltd. registered as a private equity fund manager, etc.
Qualifications
People's Republic of China, 2014
Education
Wuhan University, LL.B.
The University of Hong Kong, J.D.
Professional Experience
• Guantao Law Firm, Partner (since 2025-present)
• Shenzhen Fortune Capital Venture Capital Management Co., Ltd., Legal Compliance (2022-2025)
• Infore Group Co., Ltd., Legal Compliance (2020-2022)
• JunZeJun Law Firm, Associate (2018-2020)
• King & Wood Mallesons, Associate (2014-2017)
Working Language
• Chinese mandarin, native
• English, excellent
